“and we'll later this year announce a Phase III program for 707.”

In context

“ank you very much. As you know, we do have ongoing programs with the IDCs SV PDL1V, and Padcev all in Phase III. We're not going to wait for readout from these studies, and we'll start earlier with Phase I/II combinations this year. In fact, with those ADCs in combination with 3SBio 707. How we look at 707, it's really to be a potential backbone to replace single-agent PD-1, PD-L1. It's got a unique structure, and the preclinical data suggests potential best in class regarding high affinity for PD-1 inhibition and also -- and potentially increase anti- angiogenic activity. You've seen the overall response rate in the first-line setting of 65%. We're confident in this molecule across the cancer areas or tumor areas that -- where we have significant capability, including thoracic, GU and GI and we'll later this year announce a Phase III program for 707. Albert Bourla: Thank you, Chris. I really -- my team got me very excited about this molecule and they have presented to me a very aggressive development plan, but they plan to execute starting this year. We will share more news about the plan when we are -- later in the year when we kick off the execution. Next question please. Operator: We'll go next to Alex Hammond with Wolfe Research. Alexandria Janet Hammond: I guess one on MSN, just given your recently announced DTC patient option for purchasing Eliquis, how should we consider the applicability of this program to the remainder of your portfolio? Albert Bourla: Thank you, Alexander. I think it's very much will help. I can tell you that the direct-to-consumer was one of the 4 things that the letter of President Trump, Trump requested f”